Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
In rat hindquarter preparations, carvacrol (1 μM; 10 min pretreatment) decreases the pressor response to KCl (80 mM) and norepinephrine (1 μM). In isolated rat aortas, carvacine dramatically reduces the contraction caused by KCl (40 mM) [3].
|
---|---|
ln Vivo |
Caroverine (1.44 mg/rat; subcutaneous injection; 1.0 mL/h for 72 hours) can reduce impulse noise-induced hearing loss in rats [4].
|
Animal Protocol |
Animal/Disease Models: SD (SD (Sprague-Dawley)) rats (250-300 g) of either sex underwent pulsed noise exposure [4]
Doses: 1.44 mg/rat Doses: 20 mg/mL; sc 1.0 mL/h for 72 hrs (hrs (hours)) Experimental Results: Significant protection of the cochlea from impulse noise damage. |
References |
[1]. Chen Z, et, al. Pharmacokinetics of caroverine in the inner ear and its effects on cochlear function after systemic and local administrations in Guinea pigs. Audiol Neurootol. Jan-Feb 2003;8(1):49-56.
[2]. Denk DM, et, al. Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol. 1997 Nov;117(6):825-30. [3]. Ishida Y, et, al. Vasorelaxant action of caroverine fumarate (a quinoxaline derivative), a calcium-blocking agent. Br J Pharmacol. 1980;71(1):343-8. [4]. Duan M, et, al. Low-dose, long-term caroverine administration attenuates impulse noise-induced hearing loss in the rat. Acta Otolaryngol. 2006 Dec;126(11):1140-7. |
Molecular Formula |
C22H28CLN3O2
|
---|---|
Molecular Weight |
401.935
|
Exact Mass |
401.19
|
Elemental Analysis |
C, 65.74; H, 7.02; Cl, 8.82; N, 10.45; O, 7.96
|
CAS # |
55750-05-5
|
Related CAS # |
23465-76-1;55750-05-5 (HCl);
|
Appearance |
Solid powder
|
SMILES |
O=C1N(CCN(CC)CC)C2=C(C=CC=C2)N=C1CC3=CC=C(OC)C=C3.[H]Cl
|
InChi Key |
JRNWTJUIMRLKBV-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H27N3O2.ClH/c1-4-24(5-2)14-15-25-21-9-7-6-8-19(21)23-20(22(25)26)16-17-10-12-18(27-3)13-11-17;/h6-13H,4-5,14-16H2,1-3H3;1H
|
Chemical Name |
1-(2-(diethylamino)ethyl)-3-(4-methoxybenzyl)quinoxalin-2(1H)-one hydrochloride
|
Synonyms |
P 201-1; P-201-1; P201-1; P 2011; P-2011; P2011; Caroverine HCl; Spadon; Tinnitin; Tinnex;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~248.80 mM)
H2O : ~20 mg/mL (~49.76 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4879 mL | 12.4397 mL | 24.8793 mL | |
5 mM | 0.4976 mL | 2.4879 mL | 4.9759 mL | |
10 mM | 0.2488 mL | 1.2440 mL | 2.4879 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.